|Articles|September 16, 2015
Adverse Event Reporting by HCPs Problematic
An analysis of 10.2 million adverse report records filed with the FDA along with survey of 123 health professionals by Tufts CSDD, found voluntary adverse drug event (ADE) reporting in the United States is incomplete, inaccurate, and inefficient.
Advertisement
An analysis of 10.2 million adverse report records filed with the FDA along with survey of 123 health professionals by Tufts CSDD, found voluntary adverse drug event (ADE) reporting in the United States is incomplete, inaccurate, and inefficient.
Key findings from the studies, reported in the September/October Tufts CSDD Impact Report , included the following:
- Pharmacists are more aggressive about ADE reporting, compared to nurses and physicians.
- ADE reports submitted by patients tend to be more complete than reports submitted by health care professionals.
- Completeness and accuracy of ADE reports vary by therapeutic area, with those for CNS drugs posting the highest drug name accuracy and some of the lowest lot number completion rates.
Read the full release.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Using AI Trial-Matching Tools to Accelerate Patient AccessSeptember 8th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Using AI Trial-Matching Tools to Accelerate Patient Access
2
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
3
Beyond the Algorithm: How Human-Centered AI Design Can Drive Clinical Trial Success
4
ACT Brief Episode 7: Veeva and Merck Trial Efficiency, DCT Barriers, and Glucose Monitoring Strategies
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
